{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22(8)"],"submitter":["Yoon KH"],"funding":["In November 2015, Sanofi obtained an exclusive license from Hanmi Pharmaceutical for the worldwide development and commercialization of efpeglenatide, an experimental, long-acting diabetes treatment. The single- and repeated-dose studies were conducted by Hanmi Pharmaceutical between May 2010 and May 2013."],"pubmed_abstract":["<h4>Aim</h4>To assess the efficacy, safety and pharmacokinetic/pharmacodynamic properties of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D).<h4>Research design and methods</h4>Two randomized, double-blind, placebo-controlled phase 2 trials were conducted. The single-dose study (n = 48) was a first-in-patient, sequential dose-escalation study. Patients received a single subcutaneous injection of efpeglenatide (2-100 μg/kg) or placebo. The repeated-dose study (n = 71) was a multiple-ascending-dose trial. Patients received weekly (1, 2 or 4 mg once weekly; 8-week period) or monthly (8, 12 or 16 mg once monthly; 9-week period) subcutaneous injections of efpeglenatide or placebo (without titration).<h4>Results</h4>Both studies demonstrated dose-proportional increases in efpeglenatide serum concentrations. The median time to attain maximum serum concentration (t<sub>max</sub> ) for efpeglenatide ranged from 72 to 144 hours in the single-dose study and from 48 to 120 hours in the repeated-dose study (following final dose). Geometric mean t<sub>1/2</sub> ranged from 135 to 180 hours across studies. Peak-to-trough ratios in the repeated-dose study ranged from 1.3 to 1.4 with once-weekly dosing and from 5.9 to 12.9 with once-monthly dosing. Following a single dose of efpeglenatide 14-100 μg/kg, fasting plasma glucose and postprandial plasma glucose levels were decreased at week 1 and remained below baseline levels for ≥3 weeks post-dosing. Repeated doses of efpeglenatide led to significant reductions in glycated haemoglobin vs placebo. In both studies, efpeglenatide was generally well tolerated. Gastrointestinal disorders were the most frequently reported treatment-emergent adverse events in efpeglenatide-treated patients.<h4>Conclusions</h4>The delayed t<sub>max,</sub> long half-life, and low peak-to-trough ratios observed demonstrate potential for improved efficacy and dosing flexibility, with good tolerability of efpeglenatide in patients with T2D."],"journal":["Diabetes, obesity & metabolism"],"pagination":["1292-1301"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7383501"],"repository":["biostudies-literature"],"pubmed_title":["Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes."],"pmcid":["PMC7383501"],"pubmed_authors":["Trautmann ME","Hompesch M","Stewart J","Kwon SC","Yoon KH","Kang J","Sorli CH"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes.","description":"<h4>Aim</h4>To assess the efficacy, safety and pharmacokinetic/pharmacodynamic properties of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D).<h4>Research design and methods</h4>Two randomized, double-blind, placebo-controlled phase 2 trials were conducted. The single-dose study (n = 48) was a first-in-patient, sequential dose-escalation study. Patients received a single subcutaneous injection of efpeglenatide (2-100 μg/kg) or placebo. The repeated-dose study (n = 71) was a multiple-ascending-dose trial. Patients received weekly (1, 2 or 4 mg once weekly; 8-week period) or monthly (8, 12 or 16 mg once monthly; 9-week period) subcutaneous injections of efpeglenatide or placebo (without titration).<h4>Results</h4>Both studies demonstrated dose-proportional increases in efpeglenatide serum concentrations. The median time to attain maximum serum concentration (t<sub>max</sub> ) for efpeglenatide ranged from 72 to 144 hours in the single-dose study and from 48 to 120 hours in the repeated-dose study (following final dose). Geometric mean t<sub>1/2</sub> ranged from 135 to 180 hours across studies. Peak-to-trough ratios in the repeated-dose study ranged from 1.3 to 1.4 with once-weekly dosing and from 5.9 to 12.9 with once-monthly dosing. Following a single dose of efpeglenatide 14-100 μg/kg, fasting plasma glucose and postprandial plasma glucose levels were decreased at week 1 and remained below baseline levels for ≥3 weeks post-dosing. Repeated doses of efpeglenatide led to significant reductions in glycated haemoglobin vs placebo. In both studies, efpeglenatide was generally well tolerated. Gastrointestinal disorders were the most frequently reported treatment-emergent adverse events in efpeglenatide-treated patients.<h4>Conclusions</h4>The delayed t<sub>max,</sub> long half-life, and low peak-to-trough ratios observed demonstrate potential for improved efficacy and dosing flexibility, with good tolerability of efpeglenatide in patients with T2D.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2025-04-29T10:51:50.987Z","creation":"2025-04-06T19:41:39.671Z"},"accession":"S-EPMC7383501","cross_references":{"pubmed":["32175655"],"doi":["10.1111/dom.14032"]}}